Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial

NCT03174522 is registered in ClinicalTrials.gov with Ixaka Ltd as lead sponsor.

NCT NCT03174522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03174522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial
Lead sponsor
Ixaka Ltd
Phase
Phase 3
Overall status
Terminated
Start date
April 25, 2017
Completion date
February 13, 2023
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, critical limb ischemia (cli), diabetes mellitus (dm), diabetes mellitus, type 1, diabetes mellitus, type 2, peripheral arterial disease (pad)